Review



cd8 t cell isolation kit  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd8 t cell isolation kit
    Cd8 T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 515 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cell isolation kit/product/Miltenyi Biotec
    Average 99 stars, based on 515 article reviews
    cd8 t cell isolation kit - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    cd8 t cell isolation kit  (Miltenyi Biotec)
    99
    Miltenyi Biotec cd8 t cell isolation kit
    Cd8 T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cell isolation kit/product/Miltenyi Biotec
    Average 99 stars, based on 1 article reviews
    cd8 t cell isolation kit - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    gene exp cd8a mm01182107 g1  (Thermo Fisher)
    98
    Thermo Fisher gene exp cd8a mm01182107 g1
    (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of <t>CD8</t> + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.
    Gene Exp Cd8a Mm01182107 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp cd8a mm01182107 g1/product/Thermo Fisher
    Average 98 stars, based on 1 article reviews
    gene exp cd8a mm01182107 g1 - by Bioz Stars, 2026-03
    98/100 stars
    		  Buy from Supplier
    cd8 t cell isolation kits  (Miltenyi Biotec)
    99
    Miltenyi Biotec cd8 t cell isolation kits
    (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of <t>CD8</t> + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.
    Cd8 T Cell Isolation Kits, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8 t cell isolation kits/product/Miltenyi Biotec
    Average 99 stars, based on 1 article reviews
    cd8 t cell isolation kits - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    cd8a t cell isolation kit  (Miltenyi Biotec)
    99
    Miltenyi Biotec cd8a t cell isolation kit
    (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of <t>CD8</t> + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.
    Cd8a T Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8a t cell isolation kit/product/Miltenyi Biotec
    Average 99 stars, based on 1 article reviews
    cd8a t cell isolation kit - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    anti cd8a pe vio 770 reafinitytm  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti cd8a pe vio 770 reafinitytm
    (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of <t>CD8</t> + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.
    Anti Cd8a Pe Vio 770 Reafinitytm, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd8a pe vio 770 reafinitytm/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    anti cd8a pe vio 770 reafinitytm - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    ripr pd1 purified mouse cd8 t cells  (Miltenyi Biotec)
    99
    Miltenyi Biotec ripr pd1 purified mouse cd8 t cells
    (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of <t>CD8</t> + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.
    Ripr Pd1 Purified Mouse Cd8 T Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ripr pd1 purified mouse cd8 t cells/product/Miltenyi Biotec
    Average 99 stars, based on 1 article reviews
    ripr pd1 purified mouse cd8 t cells - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    naive cd8 t cells isolation kit mouse  (Miltenyi Biotec)
    97
    Miltenyi Biotec naive cd8 t cells isolation kit mouse
    (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of <t>CD8</t> + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.
    Naive Cd8 T Cells Isolation Kit Mouse, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/naive cd8 t cells isolation kit mouse/product/Miltenyi Biotec
    Average 97 stars, based on 1 article reviews
    naive cd8 t cells isolation kit mouse - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    mouse miltenyi biotec  (Miltenyi Biotec)
    99
    Miltenyi Biotec mouse miltenyi biotec
    (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of <t>CD8</t> + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.
    Mouse Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse miltenyi biotec/product/Miltenyi Biotec
    Average 99 stars, based on 1 article reviews
    mouse miltenyi biotec - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of CD8 + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.

    Journal: bioRxiv

    Article Title: “Tumor-to-endothelium mitochondrial transfer licenses endothelial cells for CD8 + T cell recognition via mitochondrial neoantigen presentation”

    doi: 10.64898/2026.01.30.702567

    Figure Lengend Snippet: (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of CD8 + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.

    Article Snippet: Housekeeping gene Rn18s (Mm03928990_g1), PDL-1 (Mm03048248_m1), Perforin (Mm00812512_m1), Ang1 (Mm01233546_g1), Ang2 (Mm00657574_s1), VECAD/Cdh5 (Mm00486938_m1), Vcam1 (Mm01320970_m1), Cxcl10 (Mm00445235_m1), Cxcl11 (Mm00444662_m1), Cxcl9 (Mm00434946_m1), Vegfa (Mm00437306_m1), Pdgfb (Mm00440677_m1), Irf3 (Mm00516784_m1), CD8a (Mm01182107_g1), Ifnγ (Mm01168134_m1), Il12a (Mm00434169_m1), Il12b (Mm01288989_m1), and Gzmb (Mm00442837_m1), TNF (Mm00443258_m1), PTEN (Mm00477208_m1), Itgax (Mm00498701_m1), Tnfsf10 (Mm01283606_m1), Tnfrsf1a (Mm00441883_g1).

    Techniques: Immunofluorescence, Expressing, Tumor Implantation, Enzyme-linked Immunospot, Western Blot, Control, Comparison

    (A) Quantification of αSMA + pericyte coverage normalized to CD31 + endothelial area following adoptive transfer (ATC) of CD4 + or CD8 + T cells in the presence of ICI, with or without IFN γ neutralization. Representative images are shown. (B) Quantification of vessel diameter across indicated treatment/transfer conditions. (C) Representative multiplex immunofluorescence images (CD31, TUNEL) with quantification of apoptotic vessels and correlation with intratumoral CD8 + abundance. (D) Representative images showing spatial proximity of CD8 + T cells and apoptotic endothelial structures (CD31 + TUNEL + ). (E) CD31 protein abundance measured by immunoblot with densitometric quantification. Data are mean ± s.e.m. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.

    Journal: bioRxiv

    Article Title: “Tumor-to-endothelium mitochondrial transfer licenses endothelial cells for CD8 + T cell recognition via mitochondrial neoantigen presentation”

    doi: 10.64898/2026.01.30.702567

    Figure Lengend Snippet: (A) Quantification of αSMA + pericyte coverage normalized to CD31 + endothelial area following adoptive transfer (ATC) of CD4 + or CD8 + T cells in the presence of ICI, with or without IFN γ neutralization. Representative images are shown. (B) Quantification of vessel diameter across indicated treatment/transfer conditions. (C) Representative multiplex immunofluorescence images (CD31, TUNEL) with quantification of apoptotic vessels and correlation with intratumoral CD8 + abundance. (D) Representative images showing spatial proximity of CD8 + T cells and apoptotic endothelial structures (CD31 + TUNEL + ). (E) CD31 protein abundance measured by immunoblot with densitometric quantification. Data are mean ± s.e.m. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.

    Article Snippet: Housekeeping gene Rn18s (Mm03928990_g1), PDL-1 (Mm03048248_m1), Perforin (Mm00812512_m1), Ang1 (Mm01233546_g1), Ang2 (Mm00657574_s1), VECAD/Cdh5 (Mm00486938_m1), Vcam1 (Mm01320970_m1), Cxcl10 (Mm00445235_m1), Cxcl11 (Mm00444662_m1), Cxcl9 (Mm00434946_m1), Vegfa (Mm00437306_m1), Pdgfb (Mm00440677_m1), Irf3 (Mm00516784_m1), CD8a (Mm01182107_g1), Ifnγ (Mm01168134_m1), Il12a (Mm00434169_m1), Il12b (Mm01288989_m1), and Gzmb (Mm00442837_m1), TNF (Mm00443258_m1), PTEN (Mm00477208_m1), Itgax (Mm00498701_m1), Tnfsf10 (Mm01283606_m1), Tnfrsf1a (Mm00441883_g1).

    Techniques: Adoptive Transfer Assay, Neutralization, Multiplex Assay, Immunofluorescence, TUNEL Assay, Quantitative Proteomics, Western Blot, Comparison

    (A) Working model of tumor-to-endothelium mitochondrial transfer enabling endothelial targeting by mitochondrial neoantigen–specific CD8 + T cells. (B) Representative microscopy images showing RENCA mtGFP signal within/adjacent to CD31 + endothelial cells in vitro . (C) Flow cytometric quantification of transfer to recipient endothelial cells across indicated tumor:endothelial ratios; representative histogram shown. (D) Representative in vivo imaging showing mtGFP tumor-mitochondrial signal within CD31 + vascular regions. (E) Representative sequencing traces showing tumor-associated mtDNA mutations (COX1, ND5) detected in endothelial purified fractions. (F–G) Human RCC tumor-to-HUVEC mitochondrial transfer visualized by microscopy (F) and quantified by flow cytometry (G). (H) Detection of tumor-associated mtDNA variants in matched RCC tumor and CD31 compartments with representative sequencing traces. (I-J) Pharmacologic inhibition of actin dynamics (cytochalasin B) or connexin signaling (GAP26) reduces mitochondrial transfer to endothelial cells

    Journal: bioRxiv

    Article Title: “Tumor-to-endothelium mitochondrial transfer licenses endothelial cells for CD8 + T cell recognition via mitochondrial neoantigen presentation”

    doi: 10.64898/2026.01.30.702567

    Figure Lengend Snippet: (A) Working model of tumor-to-endothelium mitochondrial transfer enabling endothelial targeting by mitochondrial neoantigen–specific CD8 + T cells. (B) Representative microscopy images showing RENCA mtGFP signal within/adjacent to CD31 + endothelial cells in vitro . (C) Flow cytometric quantification of transfer to recipient endothelial cells across indicated tumor:endothelial ratios; representative histogram shown. (D) Representative in vivo imaging showing mtGFP tumor-mitochondrial signal within CD31 + vascular regions. (E) Representative sequencing traces showing tumor-associated mtDNA mutations (COX1, ND5) detected in endothelial purified fractions. (F–G) Human RCC tumor-to-HUVEC mitochondrial transfer visualized by microscopy (F) and quantified by flow cytometry (G). (H) Detection of tumor-associated mtDNA variants in matched RCC tumor and CD31 compartments with representative sequencing traces. (I-J) Pharmacologic inhibition of actin dynamics (cytochalasin B) or connexin signaling (GAP26) reduces mitochondrial transfer to endothelial cells

    Article Snippet: Housekeeping gene Rn18s (Mm03928990_g1), PDL-1 (Mm03048248_m1), Perforin (Mm00812512_m1), Ang1 (Mm01233546_g1), Ang2 (Mm00657574_s1), VECAD/Cdh5 (Mm00486938_m1), Vcam1 (Mm01320970_m1), Cxcl10 (Mm00445235_m1), Cxcl11 (Mm00444662_m1), Cxcl9 (Mm00434946_m1), Vegfa (Mm00437306_m1), Pdgfb (Mm00440677_m1), Irf3 (Mm00516784_m1), CD8a (Mm01182107_g1), Ifnγ (Mm01168134_m1), Il12a (Mm00434169_m1), Il12b (Mm01288989_m1), and Gzmb (Mm00442837_m1), TNF (Mm00443258_m1), PTEN (Mm00477208_m1), Itgax (Mm00498701_m1), Tnfsf10 (Mm01283606_m1), Tnfrsf1a (Mm00441883_g1).

    Techniques: Microscopy, In Vitro, In Vivo Imaging, Sequencing, Purification, Flow Cytometry, Inhibition

    (A) CD31 staining levels in RCC samples stratified by presence or absence of COX1 mutation. (B) Quantification of vessel diameter (mm) stratified by COX1 mutation status. (C) Representative multiplex immunofluorescence staining (CD31, TUNEL, CD8) with quantification of CD8-associated apoptotic vessels in COX1-mutant vs COX1–wildtype tumors. (D) IFN γ ELISpot responses of human CD8 + T cells expanded against mitochondrial neoantigen peptides, showing responses to peptide stimulation compared with media control. (E) Endothelial cell stimulation assays showing IFN γ production by TAMA-specific CD8 + T cells following co-culture with peptide-pulsed HUVECs, with and without MHC class I blockade. (F) Real-time cytotoxicity assay showing killing kinetics of HUVEC targets by TAMA-specific CD8 + T cells, with or without MHC class I blockade. (G) Sorting strategy and representative imaging confirming enrichment of endothelial recipient populations following mitochondrial transfer co-culture. (H) Cytotoxicity kinetics using sorted recipient endothelial populations following mitochondrial transfer. Each dot represents one patient sample (A–C) or independent replicate (D–H).

    Journal: bioRxiv

    Article Title: “Tumor-to-endothelium mitochondrial transfer licenses endothelial cells for CD8 + T cell recognition via mitochondrial neoantigen presentation”

    doi: 10.64898/2026.01.30.702567

    Figure Lengend Snippet: (A) CD31 staining levels in RCC samples stratified by presence or absence of COX1 mutation. (B) Quantification of vessel diameter (mm) stratified by COX1 mutation status. (C) Representative multiplex immunofluorescence staining (CD31, TUNEL, CD8) with quantification of CD8-associated apoptotic vessels in COX1-mutant vs COX1–wildtype tumors. (D) IFN γ ELISpot responses of human CD8 + T cells expanded against mitochondrial neoantigen peptides, showing responses to peptide stimulation compared with media control. (E) Endothelial cell stimulation assays showing IFN γ production by TAMA-specific CD8 + T cells following co-culture with peptide-pulsed HUVECs, with and without MHC class I blockade. (F) Real-time cytotoxicity assay showing killing kinetics of HUVEC targets by TAMA-specific CD8 + T cells, with or without MHC class I blockade. (G) Sorting strategy and representative imaging confirming enrichment of endothelial recipient populations following mitochondrial transfer co-culture. (H) Cytotoxicity kinetics using sorted recipient endothelial populations following mitochondrial transfer. Each dot represents one patient sample (A–C) or independent replicate (D–H).

    Article Snippet: Housekeeping gene Rn18s (Mm03928990_g1), PDL-1 (Mm03048248_m1), Perforin (Mm00812512_m1), Ang1 (Mm01233546_g1), Ang2 (Mm00657574_s1), VECAD/Cdh5 (Mm00486938_m1), Vcam1 (Mm01320970_m1), Cxcl10 (Mm00445235_m1), Cxcl11 (Mm00444662_m1), Cxcl9 (Mm00434946_m1), Vegfa (Mm00437306_m1), Pdgfb (Mm00440677_m1), Irf3 (Mm00516784_m1), CD8a (Mm01182107_g1), Ifnγ (Mm01168134_m1), Il12a (Mm00434169_m1), Il12b (Mm01288989_m1), and Gzmb (Mm00442837_m1), TNF (Mm00443258_m1), PTEN (Mm00477208_m1), Itgax (Mm00498701_m1), Tnfsf10 (Mm01283606_m1), Tnfrsf1a (Mm00441883_g1).

    Techniques: Staining, Mutagenesis, Multiplex Assay, Immunofluorescence, TUNEL Assay, Enzyme-linked Immunospot, Control, Cell Stimulation, Co-Culture Assay, Cytotoxicity Assay, Imaging